| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是以生产中成药为主导，以“化学药、生物药”和“健康养生品”为两翼，集药品研发、制造与营销为一体的大型品牌医药集团企业。公司以“用户第一、指标第一、贡献者第一、加速创新、必须奋斗”为核心价值观，以“呵护中国儿童健康成长，保障中国儿童用药安全”、“做咱老百姓的好药”为使命，积极响应国家医药政策，在持续深耕医药领域的同时，逐步向大健康产业拓展和渗透。 品种资源是医药企业的核心资源。目前公司拥有药品批准文号1126个，其中进入国家医保目录文号551个，进入国家基本药物目录文号283个，独家品种27个（独家医保品种4个）。丰富的自有药品文号为公司持续发展奠定基础；另一方面，公司眼睛向外，在国内外寻找特色品种进行战略合作，巩固优势，持续丰富公司品种资源储备，扩大黄金单品的矩阵规模，夯实核心品类的发展优势。 凭借产品品质、用户口碑、品牌传播、渠道推广、终端掌控，公司成功打造出“小葵花”、“葵花”两大知名品牌。同时，公司持续实施战略引领、双品牌驱动、品类竞争、模式创新，不断强化终端覆盖、黄金单品群打造，推动公司经营业绩快速提升。 “一小、一老、一妇”是公司深耕的特色用药领域。儿童用药是公司第一核心战略，用妈妈心做儿童药，倾力打造“小葵花”主品牌，布局儿药品类；老年慢性病用药、妇科用药为公司成人用药领域核心优势品类，公司坚持“做咱老百姓的好药！”，打造“葵花”主品牌，布局成人药品类，打造黄金产品群。 “小葵花”品牌旗下，公司主要运作儿童药、儿童健康品。主要品类为儿童呼吸系统用药、儿童消化系统用药、儿童补益系统用药、儿童精神神经领域用药、儿童健康产品。目前，公司“小葵花”儿童药已在行业发展中取得竞争优势。小儿肺热咳喘口服液/颗粒、小儿柴桂退热颗粒、芪斛楂颗粒、小葵花露、小儿氨酚黄那敏颗粒、小儿氨酚烷胺颗粒等流量产品成为儿童、妈妈群体中的明星产品、信赖产品。 “葵花”品牌旗下，公司主要运作成人医药产品、成人大健康产品。产品涵盖呼吸感冒系统用药、消化系统用药、风湿骨病用药、心脑血管用药、妇科用药、补益用药及健康产品。其中，公司将重点打造老慢病用药、妇科用药两个品类产品及益生菌品类健康产品。目前，葵花品牌成人药在行业内与消费者心中具有较高的认可度。护肝片、胃康灵等核心品种在市场同类竞品中始终保持较高的市场份额。 营销模式上，公司采用“品牌?临床”的模式打造核心主品并带动品类产品线的组合式营销模式。其中，公司“品牌?产品线集群”的零售渠道模式在行业中处于领先位置，为众多同业所推崇和效仿。未来，公司会持续将长板做强，多措并举，强化竞争壁垒，保持和巩固公司在OTC端的领先优势。 | ||||||||||||||||||||||||
| Main Business | 各类中成药、化学药品（包括生物制药）的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 关玉秀 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 周广阔 | ||||||||||||||||||||||||
| Solicitors | 北京市天元律师事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0451-82307136 | ||||||||||||||||||||||||
| Fax No | 0451-82367253 | ||||||||||||||||||||||||
| Website | www.kuihuayaoye.com | ||||||||||||||||||||||||
| 3124893@qq.com;khyygroup@163.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 30/12/2014 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.920 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 1.500 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 8.157 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 12.206B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |